CRISPR Therapeutics
CRSP
CRSP
417 hedge funds and large institutions have $3.07B invested in CRISPR Therapeutics in 2023 Q2 according to their latest regulatory filings, with 65 funds opening new positions, 94 increasing their positions, 137 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
9% more funds holding
Funds holding: 381 → 417 (+36)
2.1% less ownership
Funds ownership: 71.49% → 69.39% (-2.1%)
31% less repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 137
Holders
417
Holding in Top 10
4
Calls
$142M
Puts
$112M
Top Buyers
| 1 | +$25.9M | |
| 2 | +$18.7M | |
| 3 | +$13.4M | |
| 4 |
CIM
Contrarius Investment Management
St. Helier,
Jersey
|
+$13M |
| 5 |
Two Sigma Investments
New York
|
+$12.3M |
Top Sellers
| 1 | -$37M | |
| 2 | -$25M | |
| 3 | -$24.9M | |
| 4 |
State Street
Boston,
Massachusetts
|
-$20.1M |
| 5 |
AC
Armistice Capital
New York
|
-$18.4M |